BridgeMD
European randomised clinical trial on mPOX Infection (EPOXI)
EU CTIS ID: 2022-501979-10-00
What this study is testing
The trial aims to provide evidence about the clinical efficacy, as assessed by time to resolution of cutaneous and mucosal lesions, of a treatment versus control group of patients with proven mPOX.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- PCR/NAAT-confirmed mPOX infection
- The presence of active skin or mucosal lesion(s)
- Signed informed consent
You likely can't join if
- Age <18 years
- Pregnant and breastfeeding patients are not eligible for inclusion in this study
- Lack of mental capacity to provide informed consent
- Trial participation is considered not in the best interest of patient
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.